Global R&D Pipeline
My Favorite
Hot Targets:
ROR1
Back
Total number of drugs
119
Phase II and later clinical stages
2.5%
Involving companies
149
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PD1/SNIPR-Based ROR1 CAR-T Cells(SPH Biotherapeutics) | PD1/SNIPR-Based ROR1 CAR-T Cells(SPH Biotherapeutics) | CAR-T | Neoplasms | PDL1 inhibitors ROR1 antagonists | SPH Biotherapeutics (Shanghai) Limited SPH Biotherapeutics (HK) Limited | SPH Biotherapeutics (HK) Limited SPH Biotherapeutics (Shanghai) Limited | Preclinical | Preclinical | - | - | - | - | - | - | - | - | PD1/SNIPR-Based ROR1 CAR-T Cells(SPH Biotherapeutics) | - | - | detail > | |
| IMD-2358 | IMD-2358 | Antibody drug conjugate (ADC) | Neoplasms | ROR1 antagonists TOP1 inhibitors | Shanghai Affinity Biopharmaceutical Co., Ltd. | Shanghai Affinity Biopharmaceutical Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | DXd | - | IMD-2358 | - | - | detail > | |
| CPD-86 | CPD-86 | Chemical drugs | Neoplasms Skin and Musculoskeletal Diseases | ROR1 antagonists | St. Joseph's University | St. Joseph's University | Preclinical | - | - | - | - | - | - | - | - | - | CPD-86 | - | - | detail > | |
| ROR1/CD3 TCE(Shanxi Province Cancer Hospital) | ROR1/CD3 TCE(Shanxi Province Cancer Hospital) | Bispecific T-cell Engager (BiTE) | Neoplasms Skin and Musculoskeletal Diseases | CD3 stimulants ROR1 antagonists | Shanxi Province Cancer Hospital | Shanxi Province Cancer Hospital | Preclinical | Preclinical | - | - | - | - | - | - | - | - | ROR1/CD3 TCE(Shanxi Province Cancer Hospital) | - | - | detail > | |
| Anti-ROR1 ADC(GlycanLink Biotech) | Anti-ROR1 ADC(GlycanLink Biotech) | Antibody drug conjugate (ADC) | Neoplasms | ROR1 antagonists | Shanghai Tangling Biomedicine Co., Ltd. | Shanghai Tangling Biomedicine Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | Anti-ROR1 ADC(GlycanLink Biotech) | - | - | detail > | |
| ABL-206 | ABL-206 | Antibody drug conjugate (ADC) | - | CD276 inhibitors ROR1 antagonists TOP1 inhibitors | ABL Bio, Inc. | ABL Bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | ABL-206 | - | - | detail > | |
| ROR1 Antagonists(Sichuan University) | ROR1 Antagonists(Sichuan University) | Small molecule drug | Neoplasms Respiratory Diseases Skin and Musculoskeletal Diseases | ROR1 antagonists | Sichuan University | Sichuan University | Preclinical | Preclinical | - | - | - | - | - | - | - | - | ROR1 Antagonists(Sichuan University) | - | - | detail > | |
| BR111A | BR111A | Antibody drug conjugate (ADC) | Neoplasms | ROR1 modulators | BioRay Biopharmaceutical Co., Ltd. | BioRay Biopharmaceutical Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | 4 | BR111A | - | - | detail > | |
| ROR1 antagonists(Bristol Myers Squibb) | ROR1 antagonists(Bristol Myers Squibb) | Small molecule drug | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease | ROR1 antagonists | Bristol Myers Squibb Co. | Bristol Myers Squibb Co. | Preclinical | - | - | - | - | - | - | - | - | - | ROR1 antagonists(Bristol Myers Squibb) | - | - | detail > | |
| Compound 9i(Sichuan University) | Compound 9i(Sichuan University) | Small molecule drug | Neoplasms | ROR1 antagonists | Sichuan University | Sichuan University | Preclinical | Preclinical | - | - | - | - | - | - | - | - | Compound 9i(Sichuan University) | - | - | detail > |
Total 119 data
1
2
3
4
5
6
...
11
12
